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1306Objective: We sought to examine long-term outcomes at the University of Wisconsin for all lung transplant re-
cipients who received lungs from donation after cardiac death donors since the initiation of this program in 1993.
Methods: Eighteen (4.2%) of the 424 lung transplantations performed in 406 patients between January 1993 and
April 2009 used lungs from donation after cardiac death donors. Outcomes for this recipient cohort were com-
pared with those for recipients who received organs from brain-dead donors.
Results: Warm ischemic time (from withdrawal of support to reperfusion of organs) was 30 17 minutes (11–93
minutes). The patient survival rates in the donation after cardiac death group (DCD group) at 1, 3, and 5 years
were 88.1%  7.9%, 81.9%  9.5%, and 81.9% 9.5%, respectively. These survival rates were not different
from those of the brain-dead donor group (BDD group, P ¼ .66). The incidence of primary graft dysfunction in
the DCD group was similar to that of the BDD group (P¼ .59). However, the incidence of airway complications
was somewhat higher in the DCD group. Freedom from bronchiolitis obliterans syndrome at 1, 3, and 5 years in
the DCD group was 80.4%  10.2%, 80.4%  10.2%, and 72.3%  11.9%, respectively, and did not differ
from the incidence of bronchiolitis obliterans syndrome in the BDD group (P ¼ .59).
Conclusions: Our data show that the long-term patient and graft survival rates after donation after cardiac death
lung transplantation were equivalent to those after brain-dead donor lung transplantation. Our findings suggest
that the use of donation after cardiac death donors can safely and substantially expand the donor pool for lung
transplantation. (J Thorac Cardiovasc Surg 2010;139:1306-15)The first successful clinical human lung transplantation (LTx)
was performed by Hardy and colleagues1 in 1963 using an al-
lograft from a cardiac-arrested donor. Over the ensuing 20
years, a number of transplantations were performed under
the same conditions, all without long-term survival. Overall,
however, the vast majority of donated organs for clinical LTx
were subsequently obtained from brain-dead donors (BDDs).
The concept of donation after cardiac death (DCD) LTx has
been reintroduced in the laboratory setting by Egan and asso-
ciates2 in 1991 and in the clinical setting with the first success-
ful LTx from a DCD donor into a patient on extracorporeal
membrane oxygenation (ECMO) for primary graft dysfunc-
tion (PGD) after single-lung transplantation (SLT).3
The shortage of donor organs remains the most critical
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The Journal of Thoracic and Cardiovascular Sursolve this problem by increasing the number of donor or-
gans, DCD donors have been used as a source of additional
organs. Because of concerns for potential lung injury caused
by unavoidable warm ischemia before the initiation of cold
flush preservation, DCD lungs have been infrequently used
for clinical LTx since the definition of brain death was im-
plemented, even though preclinical experimental evidence
has demonstrated the resilience of the lung to warm and
cold ischemia.2
In nonthoracic organ transplantation clinical studies from
several institutions have shown that organs such as the kid-
ney4 and liver5 obtained from DCD donors can function
well after implantation. The Organ Procurement and Trans-
plantation Network data show a progressive increase in the
rate of organ recovery from DCD donors (844 DCD donors
in 2008 compared with 268 in 2003), and DCD donors ac-
counted for 10% of all deceased donors in 2007 (http://
optn.transplant.hrsa.gov/). In our own organ procurement
organization, the University of Wisconsin Hospitals and
Clinics Organ Procurement Organization (UWHC–OPO),
DCD donors have accounted for more than 20% of all
deceased donors. The inability to assess the lung visually
in situ before arrest has been one obstacle to wider
acceptance of use of DCD lungs; however, there continue
to be many obstacles to acceptance of lung grafts for
transplantation, even for donors meeting standard criteria
with the ability perform full evaluation and inspection of
organs in situ. Lung use rates remain dismal in the Unitedgery c May 2010
Abbreviations and Acronyms
BDD ¼ brain-dead donor
BLT ¼ bilateral lung transplantation
BOS ¼ bronchiolitis obliterans syndrome
DCD ¼ donation after cardiac death
ECMO ¼ extracorporeal membrane
oxygenation
iNO ¼ Inhaled nitric oxide
IQR ¼ interquartile range
ISHLT ¼ International Society of Heart and
Lung Transplantation
LAS ¼ lung allocation score
LTx ¼ lung transplantation
PGD ¼ primary graft dysfunction
POD ¼ postoperative day
SLT ¼ single-lung transplantation
UNOS ¼ United Network for Organ Sharing
UWHC–OPO ¼ University of Wisconsin Hospitals
and Clinics Organ Procurement
Organization
WIT ¼ warm ischemic time
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lung donor evaluation and acceptance.
Mason and coworkers6 reported a retrospective review of
the outcomes in 36 DCD donor LTx recipients from the
United Network for Organ Sharing (UNOS) registry and
suggested that the 1-year posttransplantation survival rate
of 87% was equivalent to that after brain death donation.
Snell and colleagues7 described successful early results in
8 patients receiving transplants from DCD donors. Nonethe-
less, most publications are limited to small case series report-
ing the short-term outcomes after DCD donor LTx.7-9
According to these reports, the early outcomes of DCD
donor LTx (ie, the incidence of PGD and measures of
early graft function) are acceptable. However, the long-
term results of DCD donor lung recipients, including chronic
graft function and the incidence of bronchiolitis obliterans
syndrome (BOS), remain unclear. This study analyzed early
and late outcomes of recipients who received DCD donor
lungs at our institution since the implementation of use of
DCD donor lungs was initiated in 1993.3MATERIALS AND METHODS
Donor and Recipient Characteristics
Between January 1993 and April 2009, 424 LTx procedures from de-
ceased donors were performed in 406 patients at UWHC. Among these pa-
tients, 18 (4.2%) had lung transplants from DCD donors. The cohorts were
divided into the DCD group (n ¼ 18) and the BDD group (n ¼ 406). PGD
was defined and graded according to the International Society of Heart and
Lung Transplantation (ISHLT) definition (Table 1).10 Acute rejection and
BOS were also defined by ISHLT criteria. Patient demographics, DCD do-The Journal of Thoracic and Carnor characteristics, graft function, posttransplantation complications, and
patient and graft survival rates were assessed.
Patient characteristics are listed in Table 2. The proportion of diagnoses
was significantly different between the groups (P ¼ .02). In particular, the
frequency of retransplantation for graft failure was higher in the DCD group
(16.7% in the DCD group vs 3.9% in the BDD group). Indications for re-
transplantation for 3 patients in the DCD group were (1) grade 3 PGD re-
quiring ECMO support on postoperative day (POD) 8 after SLT for
emphysema, (2) unrelenting graft failure from diffuse alveolar damage 8
months after bilateral lung transplantation (BLT) for idiopathic pulmonary
fibrosis, and (3) severe BOS 5 years after SLT for emphysema. The propor-
tion of patients requiring pretransplantation hospitalization exceeding 3
days was significantly higher in the DCD group (33.3% vs 8.6%,
P<.01). The frequencies of the BLT procedure and use of cardiopulmonary
bypass were higher in the DCD group. However, there was not a significant
statistical difference between the groups. Warm ischemic time (WIT) was
defined as the interval between withdrawal of life support and establishing
perfusion of the donor lung with cold preservative solution, as described in
our previous publications,3-5,11 and cold ischemic time was defined as the
interval between the cold flush of the donor lung and blood reperfusion of
the lung during implantation into the recipient. The mean cold ischemic
time was similar in both groups.
DCD Donor Characteristics
DCD donor characteristics are shown in Tables 2 and 3. The mean donor
age was 30.4  14.6 years, and 12 (66.7%) DCD donors were male. The
mean age was not different between the groups. The major medical
diagnosis was trauma caused by motor vehicle accident in 8 (44.4%) DCD
donors. The median length of mechanical ventilation before withdrawal of
support was 4 days, and 7 (38.9%) DCD donors had more than 5 days of
ventilator support. Heparin was administered to all DCD donors before
withdrawal of support. The mean WIT was 30  17 minutes (11–93
minutes). The WIT in 11 (61.1%) DCD donors was less than 30 minutes.
Selection of DCD Donor Lung Recipients
The candidates for DCD LTx were determined primarily based on severity
of illness and a clinical assessment that the patient would not survive the cur-
rent condition if required to wait for a standard donor. The transplant surgeon
obtained consent for DCD donor LTx with the recipient or legal representative
in each case. In the early 1990s, there were no clinical outcome data regarding
DCD donor lung grafts, and these lungs were seldom used because of a lack of
data about potential lung damage caused by warm ischemia. Therefore the
DCD donor lungs were used for the selected patients who were consented
for DCD donor lungs and were deemed unlikely to survive while waiting
for a transplantation from a BDD because of the rapid deterioration of their
end-stage lung disease. These patients were nearly always the sickest patients
listed at our center at the time they underwent transplantation.
DCD Donor Program and Evaluation Process in the
UWHC–OPO
Our institution has a long history of using kidneys from controlled DCD
donors.4 In 1993, our program was expanded to transplantation of extrarenal
organs, such as the liver, simultaneous pancreas–kidney, and lung.11 Since
2003, the UWHC–OPO has evaluated all referrals of patients with severe
brain damage but who do not meet the criteria for brain death and whose fam-
ilies have chosen to withdraw life-sustaining therapies. Because DCD donors
frequently have preservation of brain stem reflexes, the possibility of contin-
ued respiration and sustained cardiac activity after extubation must be dis-
cussed when obtaining consent from the family. Our protocol for donor
management and lung retrieval has been refined over the past 15 years and
previously published.3-5,11-13 When consent is obtained for DCD, the
family is informed that multiorgan donation will not occur beyond 2 hours
after withdrawal of life support. If cardiopulmonary function persistsdiovascular Surgery c Volume 139, Number 5 1307
TABLE 1. Criteria for grading of primary graft dysfunction
Grade PaO2/FIO2 ratio
Radiographic
infiltrates consistent with
pulmonary edema
0 >300 Absent
1 >300 Present
2 200–300 Present
3 <200 Present
Absence of infiltrates on chest radiographic analysis is sufficient for grade 0, even if the
PaO2/FIO2 ratio is less than 300. If the subject is on a nasal cannula for oxygen or FIO2 is
less than 0.3, the subject is graded as 0 or 1 based on results of chest radiographic anal-
ysis. Any patient on extracorporeal oxygenation is automatically grade 3. Any subject
mechanically ventilated with an FIO2 of greater than 0.5 on nitric oxide beyond 48 hours
from the time of transplantation should be considered grade 3. If multiple blood gas
values are available, the worst PaO2/FIO2 ratio will be used for the purposes of this grad-
ing scheme.PaO2, Arterial partial pressure of oxygen;FIO2, fraction of inspired oxygen.
TABLE 2. Patient demographics
DCD group
(n ¼ 18)
BDD group
(n ¼ 406)
P
value
Age (y) 46.9  12.1 50.4  12.1 .20
Sex (female) 7 (38.9%) 148 (36.5%) .81
Race (white) 18 (100%) 392 (96.5%) .89
BMI (kg/m2) 23  3.9 24  4.9 .22
Diagnosis .02
COPD/emphysema 4 (22.2%) 147 (36.2%) .23
Cystic fibrosis 5 (27.8%) 64 (15.8%) .19
Retransplantation for graft
failure
3 (16.7%) 16 (3.9%) .04
a1-Antitrypsin deficiency 2 (11.1%) 47 (11.6%) >.99
Idiopathic pulmonary
fibrosis
1 (5.6%) 91 (22.4%) .14
Primary pulmonary
hypertension
1 (5.6%) 5 (1.2%) .23
Sarcoidosis 1 (5.6%) 11 (2.7%) .41
Lymphangiolyomyomatosis 1 (5.6%) 4 (1%) .20
Other 0 21 (5.2%) >.99
Pulmonary function
FVC (% predicted) 46  19 48  17 .80
FEV1 (% predicted) 26  9 30  19 .75
Continuous mechanical
ventilation
2 (11.1%) 20 (4.9%) .24
Hemodynamics
Systolic PAP (mm Hg) 41  16 40  13 .74
Mean PAP (mm Hg) 30  13 29  10 .90
PCWP (mm Hg) 13  6 14  8 .63
Cardiac index
(L $ min1 $ m2)
2.9  0.7 3.0  0.9 .97
Serum creatinine (mg/dL) 1.0  0.3 0.9  0.5 .37
Pretransplantation
hospitalization 3 d
6 (33.3%) 35 (8.6%) <.01
Time on waiting list (d) 199
(IQR, 78–649)
240
(IQR, 93–470)
.74
Bilateral lung transplantation
procedure
9 (50%) 148 (36.5%) .24
Cardiopulmonary
bypass
9 (50%) 138 (34%) .16
Cold ischemic time (min) 392  96 393  141 .59
Donor age (y) 30.4  14.6 32.0  13.2 .56
Donor sex (female) 6 (33.3%) 139 (34.2%) .94
Donor race (white) 18 (100%) 359 (88.4%) .31
DCD, Donation after cardiac death; BDD, brain-dead donor; BMI, body mass index;
COPD, chronic obstructive pulmonary disease; FVC, forced vital capacity; FEV1,
forced expiratory volume in 1 second; PAP, pulmonary arterial pressure; PCWP, pul-
monary capillary wedge pressure; IQR, interquartile range.
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where they will receive end-of-life care. During the time that consent is ob-
tained, the family is fully informed about the procedure, including any med-
ications that might be given, such as phentolamine and heparin. Once cardiac
death is declared by the physician in charge of end-of-life care for the donor,
an additional 5 minutes must elapse, as described in the 1997 Institute of
Medicine guidelines,14 before an incision is made.
Organ Procurement and Preservation
Our techniques of organ procurement and preservation during DCD have
been described.3,11,13 When allowed by local hospital DCD protocols, while
the patient is fully supported, 30,000 units of heparin and 10 mg of
phentolamine are administered intravenously to prevent vasospasm and to
facilitate subsequent organ flushing. The patient’s physician of record
withdraws life support by stopping intravenous medications and
extubation. Variable periods of hypotension and hypoxia occur after the
withdrawal of life support and before cessation of all cardiopulmonary
function. Our current acceptance criteria of WIT for DCD donor lungs is
up to 60 minutes; however, one patient in this series had 93 minutes of
WIT. Five minutes after the declaration of cardiac death, the donor was
reintubated and reventilated by means of hand bagging after suctioning.
Median sternotomy is performed, 4 L of preservative solution is infused
in situ through the main pulmonary artery, and 2 L of retrograde flush is
infused through the pulmonary veins. The majority of our donors were
perfused with University of Wisconsin Solution, but the last 2 patients
received Perfadex (Vitrolife, Go¨teborg, Sweden) as the preservation
solution. The lungs were then stored in preservation solution at 4C and
returned to our center. All DCD donor lung organs were recovered by
staff surgeons from the UWHC, nearly all by the same surgeon
performing the implantation.
Posttransplantation Bronchoscopy and Surveillance
All lung transplant recipients receive surveillance bronchoscopies with
bronchoalveolar lavage and transbronchial biopsies graded according to cri-
teria set by the ISHLT Lung Rejection Study Group15 at posttransplantation
weeks 2, 6, 12, 18, 26, 40, and 52 to detect rejection, infection, or both.
Bronchoscopies are also performed when necessary for clinical indications,
with follow-up bronchoscopies performed 4 weeks after a previous bron-
choscopy in which acute cellular rejection of any grade was detected. All
biopsy results were retrospectively reviewed for this study.
Data Acquisition and Follow-up
The institutional review board of our institution approved this study.
Data were collected prospectively and analyzed retrospectively. The LTx
database was reviewed for demographic, operative, perioperative, and out-1308 The Journal of Thoracic and Cardiovascular Surcome data. Follow-up was obtained through outpatient chart review. The
longest follow-up was 5597 days (median of 1380 days and interquartile
range [IQR] of 115–1782 days for the DCD group and median of 1269
days and IQR of 419–2569 days for the BDD group).
Statistical Analysis
Categorical data were summarized with frequency distributions and per-
centages. The means  standard deviations were calculated for variables
that were normally distributed, and the medians with IQRs were presented
for those that were skewed. Continuous variables were compared by usinggery c May 2010
TABLE 3. DCD donor characteristics
DCD group
Medical diagnosis
Trauma 8 (44.4%)
Cerebrovascular accident 5 (27.8%)
Anoxia 4 (22.2%)
Other 1 (5.6%)
Pulmonary function
Last PO2/FIO2 ratio 457  67
Length of mechanical ventilation (d) 4 (IQR, 2–9.5)
Inotropic support 6 (33.3%)
Pretreatment
Heparin 18 (100%)
Phentolamine 16 (88.9%)
Warm ischemic time from withdrawal to perfusion (min)
Mean 30  17
10–20 5 (27.8%)
21–30 6 (33.3%)
31–60 6 (33.3%)
61 1 (5.6%)
Organs recovered
Kidney 18 (100%)
Liver 16 (88.9%)
Pancreas 14 (77.8%)
DCD, Donation after cardiac death; PO2, arterial partial pressure of oxygen; FIO2, frac-
tion of inspired oxygen; IQR, interquartile range.
TABLE 4. Postoperative outcomes
DCD group BDD group P value
Primary graft dysfunction .59
Grade 0 or 1 12 (66.7%) 300 (73.9%)
Grade 2 or 3 6 (33.3%) 106 (26.1%)
Required ECMO support 0 26 (6.4%) .62
Inhalation of nitric oxide 12 (66.7%) 158 (38.9%) .02
48 h of inhalation 3 (16.7%) 92 (22.7%) .77
Reintubation 2 (11.1%) 81 (20.0%) .55
Mechanically ventilated
period (d)
1.3 (IQR, 0.9–3.3) 1.8 (IQR, 1.0–4.0) .33
48 h of ventilator
support
6 (35.3%) 186 (47.1%) .34
Reoperation 1 (5.6%) 62 (15.3%) .49
Dialysis 1 (5.6%) 20 (4.9%) .61
Length of ICU stay (d) 4 (IQR, 3–8) 6 (IQR, 3–13) .18
Length of hospital
stay (d)
17 (IQR, 15–23) 20 (IQR, 14–33) .43
Hospital mortality 1 (5.6%) 30 (7.4%) >.99
Readmission<30 d 5 (27.8%) 112 (27.6%) >.99
Acute rejection*
A1 5 (27.8%) 218 (53.7%) .03
A2 6 (33.3%) 178 (43.8%) .38
A3 0 39 (9.6%) .39
DCD, Donation after cardiac death; BDD, brain-dead donor; ECMO, extracorporeal
membrane oxygenation; IQR, interquartile range; ICU, intensive care unit. *The total
number of recipients who experienced each grade of acute rejection during the follow-
up period. At our institution, surveillance bronchoscopies are usually preformed at
posttransplantation weeks 2, 6, 12, 18, 26, 40, and 52.
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nal variables were compared by means of the c2 or Fisher exact tests, as ap-
propriate. The Kaplan–Meier method was used to assess LTx patient
survival, lung graft survival, and freedom from airway complications and
BOS. Log-rank tests were used to assess statistical significance in survival
differences between the DCD and BDD groups. All analyses were per-
formed with the SPSS statistical software program (SPSS for Windows ver-
sion 16.0; SPSS, Inc, Chicago, Ill).
RESULTS
Primary Graft Dysfunction
Postoperative outcomes are shown in Table 4. The inci-
dence of PGD was not different between the groups. Three
(16.7%) recipients in the DCD group were given diagnoses
of grade 3 PGD within 72 hours after transplantation, but all
3 recovered graft function and were discharged to home.
There were no patients who required ECMO support in the
DCD group. The incidence of posttransplantation use of in-
haled nitric oxide (iNO) was significantly higher in the DCD
group (66.7% vs 38.9%, P ¼ .02). However, the frequency
of iNO use at 48 hours or later was no different between the
groups. Figure 1, A, represents the changes in recipients’ ar-
terial partial pressure of oxygen/fraction of inspired oxygen
ratios for the first 72 hours after LTx. The mean values of
partial pressure of oxygen/fraction of inspired oxygen ratios
at each time point did not differ between the groups.
Acute Rejection
The incidence of acute cellular rejection for each grade
is shown in Table 4. The frequency of A1 rejection wasThe Journal of Thoracic and Carsignificantly lower (27.8% vs 53.7%, P ¼ .03), and no
patients had A3 rejection in the DCD group. Six (33.3%)
DCD donor recipients experienced acute rejection of A2
or greater versus 188 (46.3%) recipients in the BDD group.
The proportion of acute rejection of grade A2 or greater
tended to be lower in the DCD group (P ¼ .09).Airway Anastomotic Complications
Airway anastomotic complications that were observed in-
cluded bronchial stenosis, dehiscence, excessive granulation
tissue formation, and fistulae that required any surgical
revision and/or bronchoscopic interventions, such as balloon
dilatation, stent replacement, and debridement. During the
study period, these complications were observed in 5
(27.8%) patients in the DCD group versus 52 (12.8%) in
the BDD group (P ¼ .08). One patient in the DCD group
had a successful retransplantation of the right lung after a com-
plete dehiscence of the right-sided bronchial anastomosis rec-
ognized on POD 12 after a BLT. This was likely due to
technical failure at implantation. Four patients had broncho-
scopic intervention for bronchial stenosis on POD 38 after
SLT, POD 39 after BLT, POD 39 after SLT, and POD 76 after
BLT, respectively. The airway complication was associated
with Aspergillus species infection of the anastomosis in
2 patients. Freedom from airway anastomotic complications
requiring treatment is shown in Figure 2, A. The rates ofdiovascular Surgery c Volume 139, Number 5 1309
FIGURE 1. Posttransplantation pulmonary function. A, Recipient partial pressure of oxygen (PO2)/fraction of inspired oxygen (FIO2) ratios for the first 72
hours after lung transplantation (LTx). B, Percent predicted forced expiratory volume in 1 second (FEV1) after LTx. DCD, Donation after cardiac death; BDD,
brain-dead donor.
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significantly lower than those in the BDD group (P ¼ .02).
Chronic Pulmonary Function and BOS
The changes in percent predicted forced expiratory volume
in 1 second during the study period are shown in Figure 1, B.
The mean values for percent predicted forced expiratory vol-
ume in 1 second at each time point did not differ betweenFIGURE 2. A, Freedom from airway anastomotic complications requiring treat
survival. D, Graft survival. DCD, Donation after cardiac death; BDD, brain-dea
1310 The Journal of Thoracic and Cardiovascular Surthe groups. Figure 2, B, shows the freedom from BOS (grades
1, 2, and 3) for both groups. The rates of freedom from BOS
were not different between the groups (P ¼ .59).Recipient and Graft Survival
Recipient and graft survival rates are shown in Figure 2, C
and D. These survival rates were not different between thement. B, Freedom from bronchiolitis obliterans syndrome (BOS). C, Patient
d donor.
gery c May 2010
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vival). In the DCD group 5 patients died during the study pe-
riod. Causes of death were small bowel infarction and
multiple system organ failure on POD 1, BOS on POD
305, metastatic colon cancer after 2.9 years, non–small
cell cancer on the native lung after 5.6 years, and multiple
system organ failure after 8.8 years, respectively.
DISCUSSION
Our cohort of 18 consecutive recipients of lung trans-
plants with organs recovered from controlled DCD donors
is the largest experience from a single center reported in
the literature to date. Our patient and graft survival rates
plus posttransplantation pulmonary function were not differ-
ent for recipients of lungs from DCD donors versus recipi-
ents given organs from BDDs. Our longest surviving
recipient with functioning lung grafts from a DCD donor
is now over 6 years after transplantation, and chronic
DCD donor lung graft function (including the prevalence
of BOS after transplantation) was equivalent to that of recip-
ients of BDD lungs.
PGD continues to be a significant cause of early morbidity
and mortality after LTx regardless of donor type.16 Accord-
ing to published small case series using controlled DCD do-
nor lung allografts, the incidence of grade 3 PGD ranged
from 13% to 20%, an incidence that is similar to that seen
with BDD LTx.7-9 Our results also demonstrate that early
DCD donor lung allograft function was good, and the
incidence of severe PGD in the DCD donor group was not
increased in comparison with that of the allografts from
BDDs. None of the DCD donor recipients required
postoperative ECMO for graft dysfunction.
The unique physiologic features of the lung might con-
tribute to its tolerance of ischemia. Lung parenchymal cells,
unlike those from other solid organs, do not rely solely on
perfusion for cellular respiration and could maintain tissue
adenosine 50-triphosphate levels as long as oxygen was sup-
plied.17 Van Raemdonck and colleagues18 demonstrated that
postmortem ventilation added to the viability of lungs during
the warm ischemic period by providing alveolar expansion
and oxygenation. Neyrinck and coworkers19 showed that
in an animal model of isolated reperfusion DCD donor
lung grafts with 1 hour of WIT were less susceptible to
PGD than lungs retrieved after 5 hours of in situ mechanical
ventilation after brain death. The time of onset of relevant is-
chemic allograft injury and the tolerable duration of WIT is
unknown. The Madrid group20 reported that grade 3 PGD
occurred in 27% of recipients after uncontrolled DCD
LTx (mean WIT, 118 minutes), and the 1-year mortality of
31% suggests that longer ischemic time is directly associ-
ated with early poor outcomes.
In our experience the recipients of DCD donor lungs re-
ceived iNO therapy more frequently than BDD recipients.
This could have contributed to better oxygenation duringThe Journal of Thoracic and Carthe acute phase after LTx in the DCD group (Figure 1, A).
Although increased use of iNO was observed in the DCD
group, the incidence of PGD was equivalent in the 2 groups.
The decision to use iNO was made based on the clinical as-
sessment that the recipient’s condition at the time of trans-
plantation warranted its use to provide the optimal
conditions for both the graft and recipient physiology at re-
perfusion. Inhalation of nitric oxide has been investigated as
a potential intervention to prevent the development of signif-
icant PGD, given the effects of iNO on pulmonary vasodila-
tion, capillary integrity, and prevention of leukocyte
adhesion and platelet aggregation.21 In a prospective, ran-
domized, blinded clinical trial, Meade and associates22
were not able to show any difference in PGD incidence
with prophylactic administration of iNO in the patients re-
ceiving transplants from BDDs. No prospective data exist
regarding the use of iNO in DCD donor LTx; however, pro-
tective effects of iNO after warm ischemia in DCD donor
lungs have been reported in the laboratory, as demonstrated
by better oxygenation and reduction in ischemia–reperfu-
sion injury.23 Further evaluation is necessary to detect and
confirm a beneficial effect of iNO in DCD donor LTx.
Airway complications can have a critical effect on out-
come. The reported incidence of airway complications
varies considerably, from 1.6% to 33%, but most centers
have a 7% to 18% rate with an associated mortality of
2% to 4%.24 Although the presence of airway complica-
tions does not appear to have a significant effect on survival,
airway complications could lead to increased costs and de-
creased quality of life. In the present study the incidence
of airway complications requiring treatments was higher in
the DCD group, but no deaths occurred as a consequence
of airway complications. This airway complication was
likely due to technical failure and not ischemia. All other air-
way issues were minor and were managed endoscopically,
generally as outpatients, by one surgeon, and none of these
patients required reoperation. The number of patients in this
series does not permit further conclusions regarding a direct
relationship between WIT in DCD donor LTx and airway
complications. The increased incidence of even minor air-
way complications in the DCD group does raise concern re-
garding the effect of warm ischemia on bronchial healing. It
has been suggested that the central airways might be more
susceptible to impaired perfusion and warm ischemia than
lung parenchymal cells. Binns and colleagues25 found
a higher incidence of necrotic changes in a porcine model
of LTx at the anastomoses after 21 days in lung transplants
from DCD donors after 60 minutes of WIT compared with
the incidence for BDDs. The authors suggested that lack
of perfusion to the moderate and large airways might con-
tribute to airway ischemic damage after LTx. The use of
bronchial clamping during implantation on their animal
model might have increased the risk of injury. In contrast,
other groups26 did not find any difference in bronchialdiovascular Surgery c Volume 139, Number 5 1311
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cedure. Clearly, a technically sound bronchial anastomosis
in DCD donor lung transplants is no less important than stan-
dard donor LTx.
The incidence of A1 acute rejection was lower in our
DCD group. The DCD donors have a theoretic benefit in
preventing the detrimental effects caused by brain death,
such as hemodynamic instability associated with an increase
in serum catecholamines, the occurrence of cytokine
storm,27 and increased organ immunogenicity, as suggested
in other solid-organ transplantions.28 These potential bene-
ficial effects of using lungs from DCD donors could possi-
bly contribute to improved survival and graft function,
as well as a decreased incidence of acute rejection, as
observed in current small case series, including our own
experience.7-9
Chronic graft rejection/BOS remains a major cause of late
death for lung transplant recipients. The recent ISHLT report
shows that BOS accounts for approximately 30% of late
deaths after primary LTx, and 51% of lung transplant recip-
ients had BOS within 5 years after primary LTx.29 A reason-
ably accurate determination of the incidence and prevalence
of various stages of BOS has yet to be determined for recip-
ients of DCD donor lung transplants. Although our cohort of
DCD donor recipients is relatively small, our results suggest
that the incidence of BOS is not increased for the DCD donor
lungs. Based on our results, it appears that incidence of acute
rejection and BOS is no worse in patients undergoing DCD
donor LTx.
Mason and colleagues6 indicated that the recipients of
DCD donor lungs had lower lung allocation scores (LASs;
mean LAS, 32) in a recent UNOS data analysis for DCD do-
nor LTx, and they suggested that there was a tendency for
DCD donor organs to be given to less ill patients. This could
be interpreted as reflecting a bias to use DCD donor organs
in patients who are less ill (because of perceived organ infe-
riority) or patients with relatively low scores because of their
recipient indication (eg, diagnosis of severe chronic obstruc-
tive pulmonary disease) who are much less likely to receive
BDD organs than waitlisted patients with high LASs. Our
experience stands in contrast to this observation. It has
been our practice to restrict DCD donor LTx to patients
deemed too ill to survive the waiting time for BDD donors.
After determining LASs, those recipients with disease pro-
ducing a lower LAS and common blood type that would
make it unlikely that they would receive a lung offer within
a time frame allowing functional survival on the wait list
have also been offered DCD donor lungs. More recipients
underwent retransplantation with DCD donor lungs for the
pretransplantation diagnosis of graft failure. Six (33.3%) pa-
tients in the DCD group had pretransplantation hospitaliza-
tion that exceeded 3 days, and 2 patients required ventilator
support before transplantation. One patients with cystic fi-
brosis in the post-LAS era had an LAS of 90 and was intu-1312 The Journal of Thoracic and Cardiovascular Surbated for 4 days with severe hemoptysis and partial pressure
of carbon dioxide in the 90s, and this patient had previously
undergone pleurodesis on the right side. The DCD donor
met extended criteria despite a severe contusion on the right
side. Successful BLT was performed, and the patient was
discharged within 2 weeks with no acute complications.
Clearly the use of DCD donors can be used to salvage
a patient at high risk of dying while awaiting LTx.
Another finding from the UNOS data analysis was
a higher use of BLT procedure in the DCD LTx group.6
The authors suggested that the increased use of BLT might
have contributed to improved survival in the DCD group.
This was not observed in our study in which half the
patients underwent SLT, especially in the early experience.
In addition, we did not prioritize the use of the BLT pro-
cedure for DCD donor lung recipients, and the indication
of BLT was identical for both DCD donor and BDD
lung recipients.
Although the use of DCD donors has been proposed to
expand the donor pool, DCD donor lungs are still seldom
used. In fact, the UNOS data show only 36 DCD donor lungs
have been used to date, indicating that only 0.2% of all
deceased donors in the past 20 years have been DCD
donors.6 In our experience this rate was 4.3% over
a 16-year period.
There are multiple reasons that might explain why the
LTx community has been slow to adopt DCD donor LTx.
First, the lungs cannot be assessed in situ visually before ar-
rest and perfusion. Second, warm ischemic injury cannot be
avoided when DCD donor lung allografts are procured, and
therefore the use of DCD donor lungs might increase the risk
of PGD and graft failure. Additionally, DCD donor lungs
might be more susceptible to aspiration during the time pe-
riod from extubation to cardiorespiratory arrest. Lastly, the
use of DCD donor lungs can raise issues of donor manage-
ment and procurement that require an increased level of co-
operation between organ procurement organization and
surgical teams. We believe that the gradual accumulation
of experience in DCD donor LTx, including data from cen-
ters such as our own, will lead to the recognition of DCD do-
nor lungs as a significant, underused, and safe source of
donor lungs.
Limitations of this study include the retrospective analysis
of our data. Our clinical data were obtained by means of
chart review, which has inherent limitations that include ac-
cess to and accuracy of the recorded data. Additionally, as
a retrospective observational study, it can be subject to selec-
tion bias and incomplete data collection. However, the data
used in the analysis were all prospectively obtained in our
transplantation database for all patients in both the DCD
and BDD groups. In the DCD group the number of patients
with idiopathic pulmonary fibrosis was small, and these pa-
tients are known to have worse survival than most other re-
cipient indications for LTx. This might have led to thegery c May 2010
De Oliveira et al Cardiothoracic Transplantationperception that outcomes for the DCD donor cohort do
not differ significantly in comparison to outcomes for
recipients of BDD lungs. Because the number of DCD
donor recipients included in the study is small, the analysis
of larger cohorts of recipients from other centers or the
UNOS database is required to determine whether outcomes
for larger numbers of DCD donor recipients differ from our
own observations.
Despite the limitations of our data in DCD donor LTx, we
view DCD donor LTx as an appropriate procedure for se-
lected recipients. The DCD donor lungs can be particularly
useful if BDD organs cannot be obtained for patients with
rapid deterioration and high likelihood of mortality if urgent
transplantation cannot be performed. Although our observed
recipient outcomes with lung transplants from DCD donors
have been equivalent to our outcomes for recipients who re-
ceived lungs from BDDs, additional evaluation of the effect
of LTx on various outcome parameters with lungs from
DCD donors is needed.CONCLUSION
We have reported our 15-year single-center experience in
LTx from DCD donors. Our data show that the long-term pa-
tient and graft survival rates after DCD donor LTx were
equivalent to those after BDD LTx. Although the cohort is
small and further evaluation is necessary to confirm our find-
ings, our data suggest that the use of DCD donors can sub-
stantially expand the donor pool for LTx. Furthermore, the
success of DCD donor LTx will help improve the lung use
rate, which remains unacceptably low. The advent of ex
vivo perfusion and assessment of lungs now in clinical use
in several centers worldwide will substantially improve the
ability to use lungs now classified as nonuseable, including
DCD donor lungs.T
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Dr Dirk E. M. Van Raemdonck (Leuven, Belgium). I would
like to thank Dr Osaki and colleagues for a clear presentation
reporting an in-depth analysis of the late outcomes in a cohort of
18 lung transplant recipients from so-called Maastricht Category
III controlled non–heart-beating donors. The LTx group at the Uni-
versity of Wisconsin is to be congratulated with this largest and
longest single-center series on LTx from DCD donors reported
thus far. The experience of the group dates back to 1993, when
Bob Love got interested and started the use of lungs from this
type of donor in whom other organs, like the kidney, liver, and pan-
creas, were already recovered for transplantation at Madison.
The authors conclude that the long-term patient and graft sur-
vival in lung transplant recipients from donors after cardiac death
are equivalent to those from donors after brain death and that these
donors therefore could be safely used to expand the donor pool.
Nevertheless, the reported doubled incidence of bronchial compli-
cations in these recipients might be a concern that should be further
investigated.
I have 3 questions for the presenter that I will pose one at a time.
The authors define the WIT as the period between the with-
drawal of life support, extubation, and the start of cold perfusion,
on average about 30 minutes. In my opinion this definition is not
entirely correct because in some donors spontaneous breathing
continues after extubation and the blood pressure remains sufficient
to perfuse the organs for a longer period of time, and therefore the
lungs cannot be considered as being ischemic already. To compare
results between different institutions across the world and to enter
data in an international register, such as the one from the ISHLT, we
should agree on the same definition of warm ischemia: either from
cardiac arrest until cold flush perfusion or when the blood pressure
in the donor decreases to less than 50 mm Hg. Therefore my ques-
tion is this: Can the authors comment on this definition and also
provide us with the exact time between cardiac arrest or electrome-
chanical dissociation and the start of cold perfusion?
Dr Osaki. Thank you very much, Professor Van Raemdonck, for
your kind comments and the question about the appropriate defini-
tion of WIT. Dr Snell and colleagues, the group from Australia, sug-
gested in a recent publication that the definition of WIT should be
considered as the interval between starting at a systolic blood pres-
sure of less than 50 mm Hg and the initiation of cold flush preserva-
tion of the organs for controlled DCD donors. We agree with this
definition. In our organ procurement organization, since 2006, the
changes in hemodynamics from extubation to cardiac arrest are
recorded. However, 15 of 18 cases DCD donor LTx were performed
before that time, and the data were not documented. Thus we were
not able to obtain records of the hemodynamic changes during the
time between extubation and declaration of death on most DCD
donors. In terms of the exact time between cardiac arrest and cold
flush of preservation solution, the mean time was 9 minutes.
Dr Van Raemdonck. All donors were extubated in the operat-
ing room, and some donors were returned to the ward if cardiac
arrest did not occur within 2 hours after withdrawal of support.
Can the authors tell us what percentage of organs could not be re-
covered from these potential donors and whether they believe that
any sedative drugs could be given to improve the donor’s comfort
and relieve the family from further awaiting the inevitable death in
the hours thereafter?1314 The Journal of Thoracic and Cardiovascular SurDr Osaki. During the study period, from January 1993 to April
2009, 269 DCD donor procurements were performed in our local
organ procurement organization. From those, 18 DCD donor lungs
were used, indicating a lung recovery rate of 6.7%. Although we
tried, we could not identify the number of potential DCD donors
in which cardiac arrest did not occur and were returned to the inten-
sive care unit or hospital ward. In addition, the total number of
DCD donor offers made to our program was not available from
our database. In terms of care of DCD donor candidates, I cannot
make any comments about the use of sedative drugs or end-of-
life management for those DCD donor candidates; however, I am
sure those were applied by the physicians managing the donor
candidates.
Dr Van Raemdonck. Finally, the freedom from airway compli-
cations was significantly lower in recipients of organs from DCD
donors. This raises the question of whether the additional warm
ischemic interval contributes to the damage of the larger airways
subjected to impaired healing. The use of an additional retrograde
pulmonary flush delivered through the 4 pulmonary veins is be-
lieved to preserve the bronchial tree better through collateral perfu-
sion of the bronchial arteries. Did your group at Wisconsin
implement such a retrograde flush in your DCD donors, and if
so, was this equally compared between both groups?
Dr Osaki. We appreciate your suggestion on a possible method
to prevent airway complications in the DCD donor lung grafts. The
possibility of increased airway complications deserves further in-
vestigation. About the specific question regarding the use of retro-
grade flush to the pulmonary veins, I can say that this has been part
of our routine technique of lung graft recovery. In an animal study
with a pig model, Binns and colleagues suggested that central
airways might be more susceptible to the lack of perfusion during
ischemia than lung parenchymal cells, which can maintain some
aerobic metabolism through ventilation. Certainly the effects of
warm ischemia on bronchial healing deserve further investigation.
Dr Van Raemdonck. Once again, I congratulate you on a nice
presentation. Thank you.
Dr Love. Dirk, I can help with some of those question because in
point of fact, none of the authors were involved primarily with any
of these cases except for the case of bronchial dehiscence. That
bronchial dehiscence, which I repaired myself, was a technical
problem and not ischemia as reported here. None of the other bron-
chial problems in the initial 17 patients were a major problem for
the patient and were managed bronchoscopically without signifi-
cant morbidity.
The development of DCD donor LTx as a clinical reality during
my tenure at the University of Wisconsin was adopted over many
years. It has been gratifying to see the adoption of the techniques
of donor management and selection, recipient selection, and valida-
tion of my results at many centers in Europe, North America, and
Australia. Retrograde flush at procurement was used in all patients,
and over the years, there was about 30% occurrence of nonretrieval
of lungs when going out for procurement.
Dr Bryan F. Meyers (St Louis, Mo). I think this is something
that is a great idea in principle, but when it gets down to the spe-
cifics, it becomes more challenging to evaluate. When Dr Love
started doing this, I am sure he was extremely selective about the
DCD donors that he accepted and the interaction between the
DCD donor and the risk of the recipient the lung was going into.gery c May 2010
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the quality of the donor lung and then look at potential recipients for
one that is suitable. I also consider the distance and the likely length
of ischemic time. There are a lot of factors that we have already put
into the decision making that would help make this work out, and
presenting this without knowing the bias behind all those careful
selections would perhaps make this look equivalent when it is really
not as equivalent as it might seem. I agree with more data collection
to learn more about the decision making and the other unrecorded
factors, but these are great results, and they make DCD donors ap-
pear equivalent, but I think that there were a lot of accommodations
that were made to make DCD donors work out as well as possible in
the beginning.
Dr John H. Dark (Newcastle, United Kingdom). I would like to
echo what others have said about the role of Bob Love in both
originating this field and driving this particular series of patients
forward.
My question is about the PGD incidence and the use of nitric
oxide. You have clearly put a huge amount of work into collecting
these data over the years. Your PGD incidence would perhaps seem
a little higher than that been recorded in European and Australian
series, although the numbers are all small. Was there any correla-
tion between any of the preoperative variables in terms of WIT
or cold ischemic time and PGD?
Dr Osaki. Thank you very much for your question.
Actually we did analyze the correlation between the WIT or cold
ischemic time and the incidence of airway complications; however,
there was no correlation between these parameters.
Dr De Oliveira. With regard to Dr Meyers’ comments, before
we start the indiscriminate use of DCD donor lungs, I think we
have to be very careful because the definition of WIT is not yet
very clear. It goes from a few minutes in countries in which eutha-
nasia is allowed to as long as 90 minutes, as in one of the patients in
our series. There is no question that there is a selection bias as well.
Most DCD donor lungs meet standard criteria. I do not think there is
that much experience about the use of extended criteria or marginal
DCD donor lungs.
Having said that, I think this is an extremely important technique.
In many situations I believe DCD donor lungs have been used as
a salvage procedure, and I do not think those patients would have
received a lung transplant on time if they had to wait for a BDD.
Finally, I think there is a lot of potential in the future to combine
the use of the ex vivo lung perfusion system and the use of DCD
donor organs. DCD donor organs could potentially be evaluated
before LTx.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). If I can follow
up on that, we have done about 11 or 12 DCD organ transplanta-
tions and because we have the ex vivo trial going, we have made
it a policy to do ex vivo assessment of all of the DCD donor lungs
in our program before implanting them to learn a little bit more
about the process. DCD donor lungs in many cases could in fact
be better organs and not exposed to the ravages of inflammatory in-
jury of brain death and brain stem coning and so on, but on the otherThe Journal of Thoracic and Carhand, if death or cessation of circulation occurs slowly, you can go
through an agonal phase of low blood pressure and shock with the
possibility of developing a shock lung. Therefore it might well be
a less predictable organ source. I do think that the ability to be
able to assess the lung before you implant it might help us to define
which organs are going to be usable.
Dr Bartosz Kubisa (Szczecin, Poland). Thank you for your nice
presentation.
The good results that you have received with these donors, are
they far away from those of the non–heart-beating donors? Can
we also have the same good results in the future from the non–
heart-beating donors? What is the time difference in the case of
your donors and the patients when the heart actually stopped and
the explantation of lungs is after an hour or 2 or a longer period
of time?
To clarify, I understand you are referring to category I and II
donors in whom cardiac activity has already stopped? I guess the
question is this: Do you expect to get equivalently good results
with Maastricht category I and II donors as you have achieved
with the category III donors?
Dr Osaki. I do not think so.
Dr Keshavjee. I think that that is another area of interest; obvi-
ously Steen has looked at it, and Dirk Van Raemdonck and others
have explored this area as well. Andres Varela in Madrid has
performed transplantations in a number of patients. There is no
doubt that the category I and II donor lungs have a much more sig-
nificant PGD and a lower 1-year survival than what has been pub-
lished worldwide with BDDs. Once again, those are lungs that have
taken a bigger hit, and I think again that there might be some good
organs in that group, but there is more variability, and that speaks
again for the advantage of the ability to be able to test or recondition
the lungs before you implant them.
Dr Waleed Saleh (Riyadh, Saudi Arabia). You mentioned that
the airway complications after DCD donor LTX were higher?
Dr Osaki. Yes.
Dr Saleh. What were they specifically, more dehiscence or
stenosis or infection?
Dr Osaki. Actually, we had 5 airway complications. One had
ischemic bronchial dehiscence on POD 8, but the other 4 patients
had bronchial stenosis, and 2 of them had an Aspergillus species
infection.
Dr Stephen D. Cassivi (Rochester, Minn). I have a quick com-
ment. I think Bob Love and his group are to be congratulated once
more. This is especially true in this day and age of tremendous trans-
parency in transplantation in North America and when in the United
States every outcome is on the Internet within 6 months. In transplan-
tation our outcomes are scrutinized very, very closely. This has a real
potential to stifle innovation such as this. Therefore for Dr Love to
move forward with something like this is a testament to his ability
to take on risk and manage it successfully. Congratulations.
Dr Osaki. Thank you very much.
Dr Keshavjee. I think that is exactly what Tom Spray was allud-
ing to in his Presidential Address. Congratulations again, Bob.diovascular Surgery c Volume 139, Number 5 1315
